Very common adverse events reported (occurring at a frequency of ≥ 1/10) were dyspnoea, headache, flushing, chest pain, electrocardiogram ST changes, gastrointestinal discomfort, and dizziness.
Common adverse events reported (occurring at a frequency of ≥ 1/100 to < 1/10) were paraesthesia, hypoaesthesia, dysgeusia, angina pectoris, atrioventricular block, tachycardia, palpitations, other ECG abnormalities including electrocardiogram QT corrected interval prolonged, hypotension, throat tightness, throat irritation, cough, vomiting, nausea, oral discomfort, back, neck or jaw pain, pain in extremity, musculoskeletal discomfort, hyperhidrosis, malaise, and asthenia.
Adverse events should be reported to your local regulatory authority
Reporting forms and information can be found at http://laegemiddelstyrelsen.dk/da/topics/bivirkninger-og-forsoeg.
Adverse events should also be reported by phone +45 32 50 66 10,
fax +45 52 52 18 48, or by email to dupharma(at)dupharma.dk
Elsewhere in Europe
Adverse events should be reported to your local regulatory authority.
Adverse events should also be reported to firstname.lastname@example.org